BIGBEAR
PHARMACEUTICALS
Crizotinib is an oral small-molecule multi-target tyrosine kinase inhibitor, and the world’s first approved targeted antineoplastic agent for both ALK and ROS1. Its common dosage form is capsules.
AuthenticGuaranteeFast DeliveryPrivacy Clinical Background of ALK-Positive NSCLCLung cancer is one of the leading causes of cancer-related death worldwide, accounting for the highest number···【Read More】
Update: 09 Mar,2026Source: Haiou HealthViews: 69
FDA Approval AnnouncementMarch 11, 2016 -- The U.S. Food and Drug Administration (FDA) approved Xalkori (crizotinib) for the treatment of patients wit···【Read More】
Update: 09 Mar,2026Source: Haiou HealthViews: 69
FDA Approval AnnouncementNEW YORK--(BUSINESS WIRE) January 14, 2021 -- Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FD···【Read More】
Update: 09 Mar,2026Source: Haiou HealthViews: 71
FDA Approval AnnouncementOn July 14, 2022, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori, Pfizer Inc.) for adult and pediat···【Read More】
Update: 09 Mar,2026Source: Haiou HealthViews: 70
Copyright2024@ BIGBEAR All right reserved BIGBEAR
